{"doc":{"info":{"calaisRequestID":"d470f999-1ffa-9b30-15e8-c3634d747f8a","id":"http:\/\/id.opencalais.com\/RTjH76IdpBKw6H1J2xu0QQ","ontology":"http:\/\/mdaas-virtual-onecalais.int.thomsonreuters.com\/owlschema\/11.0\/onecalais.owl.allmetadata.xml","docId":"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024","document":"(EMAILWIRE.COM, September 16, 2017 ) The Global Plasma Protein Therapeutics is estimated to be at USD 19.2 Billion in 2016 and is poised to reach USD 27.56 Billion by 2021 with a CAGR of 7.5%. The use of plasma protein in the medical applications has increased significantly in the recent years. With the advancements in technology, the process for fractionating the protein from plasma has become more cost saving and efficient and is supposed to boost the plasma protein market. According to WHO reports more than half of the global blood donors belong to high income countries which constitutes 18% of the population. With rising awareness among people regarding blood donations and government initiatives, plasma derived medicine market is expected to grow at a significant rate in the coming years.\n\nBrowse market data tables and in-depth TOC of the Global Plasma Protein Therapeutics Industry to 2021 @ http:\/\/www.marketdataforecast.com\/market-reports\/global-plasma-protein-therapeutics-market-235\/\n\nPlasma is a protein rich fluid and plays a crucial role in clotting and providing immunity to diseases. By isolating the proteins from plasma, they can used for medical therapies including autoimmune, immune deficiencies, neurological and bleeding disorders. Plasma protein therapies are used to treat well-defined medical condition by replacing the deficient or missing proteins in plasma. Plasma protein therapeutics involves biological medicines either infused or injected to treat life-threatening, chronic and genetic diseases.\n\nIncreasing introduction of new plasma-derived therapies is the primary driving factor for the market. The market is also driven by a host of other factors, including rising prevalence of life threatening diseases involving immune or neurological systems and other infectious diseases like Rabies, Tetanus, Hepatitis A&B and varicella. On the contrary there are a few restraints for market which includes stringent government policies, issues pertaining to reimbursement, complexity in manufacturing.\n\nFree sample of the report is available @ http:\/\/www.marketdataforecast.com\/market-reports\/global-plasma-protein-therapeutics-market-235\/request-sample\n\nThe Global Plasma Protein Therapeutics Market is segmented based on product type as Immunoglobulins, Albumin, Coagulation Factors, alpha-1 proteinase inhibitor and others. On the basis of application the market is categorised as Hemophilia, Primary Immunodeficiency Disorder, Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency and others. Based on geographical region, the market is analysed in the regions of North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa.\n\nThe major players in the plasma protein therapeutic market are Baxter, CSL Behring, Biotest, China Biologics, Grifols, Kedrion, Octapharma, Shire Plc., and Chengdu Inst.\n\nInquire before Buying at http:\/\/www.marketdataforecast.com\/market-reports\/global-plasma-protein-therapeutics-market-235\/inquire\n\nAbout Us:\n\nMarket Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.\n\nVisit Market Data Forecast Blog @ http:\/\/www.marketdataforecast.com\/blog\/\n\nView latest Press Releases of MDF @ http:\/\/www.marketdataforecast.com\/press-releases","docTitle":"","docDate":"2017-09-16 19:41:56.679"},"meta":{"contentType":"text\/raw","processingVer":"AllMetadata","serverVersion":"OneCalais_11.0-RELEASE:169","stagsVer":"OneCalais_11.0-RELEASE-b10-2017-07-31_12:36:53","submissionDate":"2017-09-16 19:41:56.311","submitterCode":"0ca6a864-5659-789d-5f32-f365f695e757","signature":"digestalg-1|siwsNzKyg0qIds10iNONu6vSIoY=|P3qQWgth9\/ROeUYRPInswfe6qzYNFTzEdx0u003MOOc6n1IU\/itOPQ==","language":"English"}},"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/cat\/1":{"_typeGroup":"topics","forenduserdisplay":"false","score":1,"name":"Health_Medical_Pharma"},"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/cat\/2":{"_typeGroup":"topics","forenduserdisplay":"false","score":0.955,"name":"Business_Finance"},"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/lid\/DefaultLangId":{"_typeGroup":"language","language":"http:\/\/d.opencalais.com\/lid\/DefaultLangId\/English","forenduserdisplay":"false","permid":"505062"},"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/SocialTag\/1":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/SocialTag\/1","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/8e621d1f-1237-3fa5-ae59-46a66458acf5","forenduserdisplay":"true","name":"Anatomy","importance":"1","originalValue":"Anatomy"},"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/SocialTag\/2":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/SocialTag\/2","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/a4d237aa-c4e9-3f9b-a26f-70199de66284","forenduserdisplay":"true","name":"Biology","importance":"1","originalValue":"Biology"},"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/SocialTag\/3":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/SocialTag\/3","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/2b4e9812-5030-3d6e-aa8d-1629aeec4ee4","forenduserdisplay":"true","name":"Biotechnology","importance":"1","originalValue":"Biotechnology"},"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/SocialTag\/4":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/SocialTag\/4","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/82002358-3bee-30aa-bf69-d9389c02a33e","forenduserdisplay":"true","name":"Blood products","importance":"2","originalValue":"Blood products"},"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/SocialTag\/5":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/SocialTag\/5","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/0670d0dc-e598-30a8-a211-4a4cca851905","forenduserdisplay":"true","name":"Octapharma","importance":"2","originalValue":"Octapharma"},"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/SocialTag\/6":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/SocialTag\/6","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/b2dfc738-6679-391a-a27f-469cebb439eb","forenduserdisplay":"true","name":"Blood","importance":"2","originalValue":"Blood"},"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/SocialTag\/7":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/SocialTag\/7","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/d3208b9f-3115-3e47-8a11-5dea7c6b5d4a","forenduserdisplay":"true","name":"CSL Behring","importance":"2","originalValue":"CSL Behring"},"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/SocialTag\/8":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/SocialTag\/8","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/bb6593c4-7aa2-3874-b6e4-99d135dfa953","forenduserdisplay":"true","name":"Biopharmaceutical","importance":"2","originalValue":"Biopharmaceutical"},"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/SocialTag\/9":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/SocialTag\/9","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/9997d1c8-dcc2-3910-b299-681b07b09d7a","forenduserdisplay":"true","name":"Blood proteins","importance":"2","originalValue":"Blood proteins"},"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/SocialTag\/10":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/SocialTag\/10","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/f40ef609-929f-34ac-b5b0-85d7d8d3700c","forenduserdisplay":"true","name":"Blood plasma","importance":"2","originalValue":"Blood plasma"},"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/Industry\/1":{"_typeGroup":"industry","forenduserdisplay":"false","name":"Biopharmaceuticals","rcscode":"B:1731","permid":"4294951270","relevance":0.2},"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/Industry\/2":{"_typeGroup":"industry","forenduserdisplay":"false","name":"Medical Equipment, Supplies & Distribution - NEC","rcscode":"B:1707","permid":"4294951294","relevance":0.2},"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/Industry\/3":{"_typeGroup":"industry","forenduserdisplay":"false","name":"Pharmaceuticals - NEC","rcscode":"B:1729","permid":"4294951272","relevance":0.2},"http:\/\/d.opencalais.com\/dochash-1\/cc5655cb-1f25-3b01-b1fe-e9d1ce125024\/ComponentVersions":{"_typeGroup":"versions","version":["DIY-Categorization-fnr-TRCS-capx:20170627191152:20170627191152","Deals Index:201709161840:201709161840","DIY-Categorization-fnr-TRCS-indx_stsale:20170323110805:20170323110805","DIY-Categorization-fnr-TRCS-comptn:20170621141739:20170621141739","index-refineries:201705201529:201705201529","DIY-Categorization-fnr-TRCS-regs_buyb_new:20170509091609:20170509091609","config-physicalAssets-powerStations:653:653","NextTags:OneCalais_11.0-RELEASE:169","DIY-Categorization-fnr-TRCS-dis:20170418132337:20170418132337","DIY-Categorization-fnr-TRCS-splitb_r1:20170329082516:20170329082516","config-sca-DataPackage:50:50","config-companyNe:655:655","DIY-Categorization-fnr-TRCS-acb:20170502102348:20170502102348","DIY-Categorization-fnr-TRCS-levrge:20170621122109:20170621122109","DIY-Categorization-fnr-TRCS-hedge_list1:20170315123823:20170315123823","config-refreshableDIY:1:1","People Index:201709161805:201709161805","DIY-Categorization-fnr-TRCS-awlq:20170331124441:20170331124441","config-negativeSignature:653:653","DIY-Categorization-fnr-TRCS-fake1_monop_bnkcap_new:20170405133257:20170405133257","Dial4J:OneCalais_8.6-RELEASE:209","DIY-Categorization-fnr-TRCS-dbtr_new:20170315123740:20170315123740","OA Override:672:672","DIY-Categorization-fnr-TRCS-hrgt:20170427081548:20170427081548","DIY-Categorization-fnr-TRCS-xpand:20170323144646:20170323144646","DIY-Categorization-fnr-TRCS-allcemrgdvst2:20170316142831:20170316142831","DIY-Categorization-fnr-TRCS-ordr:20170313151239:20170313151239","People Override:653:653","DIY-Categorization-fnr-TRCS-hrgt_recll:20170522120000:20170522120000","index-company-oa3:201709152235:201709152235","index-vessels:201709100045:201709100045","DIY-Categorization-fnr-TRCS-brib_r1:20170329090629:20170329090629","config-forEndUserDisplay:3:3","config-refineries:653:653","DIY-Categorization-fnr-TRCS-fapm:20170713144316:20170713144316","DIY-Categorization-fnr-TRCS-class:20170315123207:20170315123207","config-cse:672:672","DIY-Categorization-fnr-TRCS-isu_dat_r:20170315124144:20170315124144","DIY-Categorization-fnr-TRCS-cnsl_sisu:20170321144134:20170321144134","DIY-Categorization-fnr-TRCS-shract_r1:20170412111808:20170412111808","config-vessels:653:653","OneCalais:OneCalais_11.0-RELEASE:169","DIY-Categorization-fnr-TRCS-mktshr2:20170705120412:20170705120412","DIY-RCS-fnr-TRCS-cavs:4:4","DIY-Categorization-fnr-TRCS-trd_tax:20170309132522:20170309132522","DIY-Categorization-fnr-TRCS-sov_2:20170522130956:20170522130956","DIY-Categorization-fnr-TRCS-bons:20170406103713:20170406103713","DIY-Categorization-fnr-TRCS-hrgt_namec:20170329090731:20170329090731","DIY-RCS-fnr-TRCS-nd:3:3","DIY-Categorization-fnr-TRCS-stx:20170530123138:20170530123138","config-physicalAssets-mines:653:653","SocialTags Index:201709031835:201709031835","BlackList:672:672","index-ports:201709091840:201709091840","config-physicalAssets-ports:653:653","DIY-Categorization-fnr-TRCS-ream:20170529065740:20170529065740","DIY-Categorization-fnr-TRCS-chld:20170524084254:20170524084254","DIY-Categorization-fnr-TRCS-allce:20170323145654:20170323145654","DIY-Categorization-fnr-TRCS-medreg:20170508120210:20170508120210","config-drugs:653:653"]},"http:\/\/d.opencalais.com\/genericHasher-1\/5715cdb9-ce78-389a-a45d-86c0bd4045df":{"_typeGroup":"entities","_type":"Technology","forenduserdisplay":"false","name":"alpha","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Technology","instances":[{"detection":"[Immunoglobulins, Albumin, Coagulation Factors, ]alpha[-1 proteinase inhibitor and others. On the basis]","prefix":"Immunoglobulins, Albumin, Coagulation Factors, ","exact":"alpha","suffix":"-1 proteinase inhibitor and others. On the basis","offset":2324,"length":5}],"relevance":0.2},"http:\/\/d.opencalais.com\/comphash-1\/f2b05d9e-a35f-3849-91b5-93697f35a4be":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"true","name":"octapharma","confidencelevel":"1.0","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[Biotest, China Biologics, Grifols, Kedrion, ]Octapharma[, Shire Plc., and Chengdu Inst.\n\nInquire before]","prefix":"Biotest, China Biologics, Grifols, Kedrion, ","exact":"Octapharma","suffix":", Shire Plc., and Chengdu Inst.\n\nInquire before","offset":2822,"length":10}],"relevance":0.2,"confidence":{"statisticalfeature":"0.644","dblookup":"0.0","resolution":"0.3502995","aggregate":"1.0"},"resolutions":[{"name":"Octapharma Nordic AB","permid":"4297902713","ispublic":"false","commonname":"Octapharma","score":0.3502995,"id":"https:\/\/permid.org\/1-4297902713"}]},"http:\/\/d.opencalais.com\/genericHasher-1\/2b0c910b-c446-3fae-9dd2-eda4e342b1cf":{"_typeGroup":"entities","_type":"MedicalCondition","forenduserdisplay":"false","name":"Hepatitis A","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/MedicalCondition","instances":[{"detection":"[other infectious diseases like Rabies, Tetanus, ]Hepatitis A[&B and varicella. On the contrary there are a few]","prefix":"other infectious diseases like Rabies, Tetanus, ","exact":"Hepatitis A","suffix":"&B and varicella. On the contrary there are a few","offset":1846,"length":11}],"relevance":0.2},"http:\/\/d.opencalais.com\/comphash-1\/cacadc10-c183-3adf-afb2-ae9f293094da":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"true","name":"Shire Plc.","nationality":"N\/A","confidencelevel":"1.0","confidence":{"statisticalfeature":"0.823","dblookup":"0.0","resolution":"0.98574394","aggregate":"1.0"},"resolutions":[{"name":"SHIRE PLC","permid":"4295894723","primaryric":"SHP.L","ispublic":"true","commonname":"Shire","score":0.98574394,"id":"https:\/\/permid.org\/1-4295894723","ticker":"SHP"}],"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[China Biologics, Grifols, Kedrion, Octapharma, ]Shire Plc.[, and Chengdu Inst.\n\nInquire before Buying at]","prefix":"China Biologics, Grifols, Kedrion, Octapharma, ","exact":"Shire Plc.","suffix":", and Chengdu Inst.\n\nInquire before Buying at","offset":2834,"length":10}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/ae7bd5ec-9003-37ff-98df-282343699393":{"_typeGroup":"entities","_type":"URL","forenduserdisplay":"false","name":"http:\/\/www.marketdataforecast.com\/press-releases","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/URL","instances":[{"detection":"[latest Press Releases of MDF @ ]http:\/\/www.marketdataforecast.com\/press-releases[]","prefix":"latest Press Releases of MDF @ ","exact":"http:\/\/www.marketdataforecast.com\/press-releases","offset":3524,"length":48}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/39765c77-6f55-3c87-8cb6-662d6e75adef":{"_typeGroup":"entities","_type":"MedicalCondition","forenduserdisplay":"false","name":"chronic and genetic diseases","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/MedicalCondition","instances":[{"detection":"[infused or injected to treat life-threatening, ]chronic and genetic diseases[.\n\nIncreasing introduction of new plasma-derived]","prefix":"infused or injected to treat life-threatening, ","exact":"chronic and genetic diseases","suffix":".\n\nIncreasing introduction of new plasma-derived","offset":1509,"length":28}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/df18b91e-c25b-391d-a552-c9ae71e627e0":{"_typeGroup":"entities","_type":"Region","forenduserdisplay":"false","name":"Latin America","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Region","instances":[{"detection":"[regions of North America, Europe, Asia-Pacific, ]Latin America[ and Middle-East & Africa.\n\nThe major players in]","prefix":"regions of North America, Europe, Asia-Pacific, ","exact":"Latin America","suffix":" and Middle-East & Africa.\n\nThe major players in","offset":2653,"length":13}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/8fdace30-1c27-3f74-a25b-b9a87cb97b30":{"_typeGroup":"entities","_type":"MedicalCondition","forenduserdisplay":"false","name":"diseases","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/MedicalCondition","instances":[{"detection":"[role in clotting and providing immunity to ]diseases[. By isolating the proteins from plasma, they can]","prefix":"role in clotting and providing immunity to ","exact":"diseases","suffix":". By isolating the proteins from plasma, they can","offset":1100,"length":8},{"detection":"[including rising prevalence of life threatening ]diseases[ involving immune or neurological systems and]","prefix":"including rising prevalence of life threatening ","exact":"diseases","suffix":" involving immune or neurological systems and","offset":1744,"length":8}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/19cc1d3f-0865-39b0-b3d6-b3739cf3e66a":{"_typeGroup":"entities","_type":"Continent","forenduserdisplay":"false","name":"Africa","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Continent","instances":[{"detection":"[Asia-Pacific, Latin America and Middle-East & ]Africa[.\n\nThe major players in the plasma protein]","prefix":"Asia-Pacific, Latin America and Middle-East & ","exact":"Africa","suffix":".\n\nThe major players in the plasma protein","offset":2685,"length":6}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/c63319ec-4e5a-3ba4-a14e-09f00a45e9c0":{"_typeGroup":"entities","_type":"Organization","forenduserdisplay":"false","name":"World Health Organization","organizationtype":"governmental civilian","nationality":"N\/A","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Organization","permid":"https:\/\/permid.org\/1-404010","instances":[{"detection":"[ to boost the plasma protein market. According to ]WHO[ reports more than half of the global blood]","prefix":" to boost the plasma protein market. According to ","exact":"WHO","suffix":" reports more than half of the global blood","offset":494,"length":3}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/a12b43d5-d195-35ea-96a9-f710943bdb5a":{"_typeGroup":"entities","_type":"Position","forenduserdisplay":"false","name":"analyst","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Position","instances":[{"detection":"[of both individual and corporate clients. Our ]analyst[ team comprises expert professionals in market]","prefix":"of both individual and corporate clients. Our ","exact":"analyst","suffix":" team comprises expert professionals in market","offset":3236,"length":7}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/93c8efd3-e0a3-399f-9b77-e2d64814bcfd":{"_typeGroup":"entities","_type":"Region","forenduserdisplay":"false","name":"Asia-Pacific","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Region","instances":[{"detection":"[in the regions of North America, Europe, ]Asia-Pacific[, Latin America and Middle-East & Africa.\n\nThe]","prefix":"in the regions of North America, Europe, ","exact":"Asia-Pacific","suffix":", Latin America and Middle-East & Africa.\n\nThe","offset":2639,"length":12}],"relevance":0.2},"http:\/\/d.opencalais.com\/comphash-1\/5ca9f6b8-0bb9-31c1-b1d9-53c87d0ba07b":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"true","name":"Grifols","nationality":"N\/A","confidencelevel":"1.0","resolutions":[{"name":"Grifols, S.A.","permid":"4295889506","primaryric":"GRLS.MC","ispublic":"true","commonname":"Grifols","score":0.7441927,"id":"https:\/\/permid.org\/1-4295889506","ticker":"GRF"}],"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[Baxter, CSL Behring, Biotest, China Biologics, ]Grifols[, Kedrion, Octapharma, Shire Plc., and Chengdu]","prefix":"Baxter, CSL Behring, Biotest, China Biologics, ","exact":"Grifols","suffix":", Kedrion, Octapharma, Shire Plc., and Chengdu","offset":2804,"length":7}],"relevance":0.2,"confidence":{"statisticalfeature":"0.843","dblookup":"0.0","resolution":"0.7441927","aggregate":"1.0"}},"http:\/\/d.opencalais.com\/genericHasher-1\/052054a5-c86a-36bc-8eb5-046b822f660d":{"_typeGroup":"entities","_type":"MedicalCondition","forenduserdisplay":"false","name":"infectious diseases","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/MedicalCondition","instances":[{"detection":"[immune or neurological systems and other ]infectious diseases[ like Rabies, Tetanus, Hepatitis A&B and]","prefix":"immune or neurological systems and other ","exact":"infectious diseases","suffix":" like Rabies, Tetanus, Hepatitis A&B and","offset":1804,"length":19}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/c6554d97-ee39-366a-8730-fae866e41852":{"_typeGroup":"entities","_type":"City","forenduserdisplay":"true","name":"Biotest","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/City","instances":[{"detection":"[therapeutic market are Baxter, CSL Behring, ]Biotest[, China Biologics, Grifols, Kedrion, Octapharma,]","prefix":"therapeutic market are Baxter, CSL Behring, ","exact":"Biotest","suffix":", China Biologics, Grifols, Kedrion, Octapharma,","offset":2778,"length":7}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/bd44c6a1-0d9c-3ac6-8b1f-a69248018cba":{"_typeGroup":"entities","_type":"MedicalCondition","forenduserdisplay":"false","name":"Primary Immunodeficiency Disorder","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/MedicalCondition","instances":[{"detection":"[the market is categorised as Hemophilia, ]Primary Immunodeficiency Disorder[, Idiopathic Thrombocytopenic Purpura, Secondary]","prefix":"the market is categorised as Hemophilia, ","exact":"Primary Immunodeficiency Disorder","suffix":", Idiopathic Thrombocytopenic Purpura, Secondary","offset":2434,"length":33}],"relevance":0.2},"http:\/\/d.opencalais.com\/comphash-1\/d0c596a6-f901-302d-b4f7-c7816cdf6efb":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"true","name":"CSL Behring","confidencelevel":"1.0","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[plasma protein therapeutic market are Baxter, ]CSL Behring[, Biotest, China Biologics, Grifols, Kedrion,]","prefix":"plasma protein therapeutic market are Baxter, ","exact":"CSL Behring","suffix":", Biotest, China Biologics, Grifols, Kedrion,","offset":2765,"length":11}],"relevance":0.2,"confidence":{"statisticalfeature":"0.668","dblookup":"0.0","resolution":"0.44132257","aggregate":"1.0"},"resolutions":[{"name":"CSL Behring AG","permid":"4296880792","ispublic":"false","commonname":"CSL Behring","score":0.44132257,"id":"https:\/\/permid.org\/1-4296880792"}]},"http:\/\/d.opencalais.com\/comphash-1\/dbcd3c4b-a0bf-3fe9-ae7a-f96ae5249df7":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"false","name":"Biotest","confidencelevel":"0.46","resolutions":[{"name":"Biotest Aktiengesellschaft","permid":"4295868772","primaryric":"BIOG.DE","ispublic":"true","commonname":"Biotest","score":0.78626835,"id":"https:\/\/permid.org\/1-4295868772","ticker":"BIO"}],"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[therapeutic market are Baxter, CSL Behring, ]Biotest[, China Biologics, Grifols, Kedrion, Octapharma,]","prefix":"therapeutic market are Baxter, CSL Behring, ","exact":"Biotest","suffix":", China Biologics, Grifols, Kedrion, Octapharma,","offset":2778,"length":7}],"relevance":0.2,"confidence":{"statisticalfeature":"0.644","dblookup":"0.0","resolution":"0.78626835","aggregate":"0.46"}},"http:\/\/d.opencalais.com\/genericHasher-1\/97339684-5979-3b94-9e6e-20b947e266b6":{"_typeGroup":"entities","_type":"MedicalCondition","forenduserdisplay":"false","name":"Rabies","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/MedicalCondition","instances":[{"detection":"[systems and other infectious diseases like ]Rabies[, Tetanus, Hepatitis A&B and varicella. On the]","prefix":"systems and other infectious diseases like ","exact":"Rabies","suffix":", Tetanus, Hepatitis A&B and varicella. On the","offset":1829,"length":6}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/470e1a91-04d6-352d-ba17-b804d54ef68b":{"_typeGroup":"entities","_type":"IndustryTerm","forenduserdisplay":"false","name":"neurological systems","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/IndustryTerm","instances":[{"detection":"[ of life threatening diseases involving immune or ]neurological systems[ and other infectious diseases like Rabies,]","prefix":" of life threatening diseases involving immune or ","exact":"neurological systems","suffix":" and other infectious diseases like Rabies,","offset":1773,"length":20}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/37f0cf6b-b991-3dc8-8018-78338494cd3a":{"_typeGroup":"entities","_type":"Continent","forenduserdisplay":"false","name":"North America","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Continent","instances":[{"detection":"[ region, the market is analysed in the regions of ]North America[, Europe, Asia-Pacific, Latin America and]","prefix":" region, the market is analysed in the regions of ","exact":"North America","suffix":", Europe, Asia-Pacific, Latin America and","offset":2616,"length":13}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/2e640ba2-8c09-3ef8-a436-cbff50ffddae":{"_typeGroup":"entities","_type":"PhoneNumber","forenduserdisplay":"false","name":"27.56","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/PhoneNumber","instances":[{"detection":"[19.2 Billion in 2016 and is poised to reach USD ]27.56[ Billion by 2021 with a CAGR of 7.5%. The use of]","prefix":"19.2 Billion in 2016 and is poised to reach USD ","exact":"27.56","suffix":" Billion by 2021 with a CAGR of 7.5%. The use of","offset":150,"length":5}],"relevance":0.2},"http:\/\/d.opencalais.com\/comphash-1\/80bd8eb8-af02-3032-b06b-945cd7e9b083":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"false","name":"Baxter","nationality":"N\/A","confidencelevel":"0.431","confidence":{"statisticalfeature":"0.905","dblookup":"0.0","resolution":"0.73828393","aggregate":"0.431"},"resolutions":[{"name":"BAXTER INTERNATIONAL INC.","permid":"4295903531","primaryric":"BAX.N","ispublic":"true","commonname":"Baxter Intl","score":0.73828393,"id":"https:\/\/permid.org\/1-4295903531","ticker":"BAX"}],"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[in the plasma protein therapeutic market are ]Baxter[, CSL Behring, Biotest, China Biologics, Grifols,]","prefix":"in the plasma protein therapeutic market are ","exact":"Baxter","suffix":", CSL Behring, Biotest, China Biologics, Grifols,","offset":2757,"length":6}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/718cbaa7-e99e-387e-9f5a-2e79649ef148":{"_typeGroup":"entities","_type":"MedicalCondition","forenduserdisplay":"false","name":"Idiopathic Thrombocytopenic Purpura","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/MedicalCondition","instances":[{"detection":"[Hemophilia, Primary Immunodeficiency Disorder, ]Idiopathic Thrombocytopenic Purpura[, Secondary Immunodeficiency and others. Based on]","prefix":"Hemophilia, Primary Immunodeficiency Disorder, ","exact":"Idiopathic Thrombocytopenic Purpura","suffix":", Secondary Immunodeficiency and others. Based on","offset":2469,"length":35}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/cf6b8bb8-77c8-33d5-b212-e69bdccdf4e7":{"_typeGroup":"entities","_type":"Technology","forenduserdisplay":"false","name":"business intelligence","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Technology","instances":[{"detection":"[firm working in the area of market research and ]business intelligence[. With rich experience in research across various]","prefix":"firm working in the area of market research and ","exact":"business intelligence","suffix":". With rich experience in research across various","offset":3079,"length":21}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/46d88a26-0964-3b0f-9078-dbb59552ec2a":{"_typeGroup":"entities","_type":"MedicalCondition","forenduserdisplay":"false","name":"varicella","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/MedicalCondition","instances":[{"detection":"[ diseases like Rabies, Tetanus, Hepatitis A&B and ]varicella[. On the contrary there are a few restraints for]","prefix":" diseases like Rabies, Tetanus, Hepatitis A&B and ","exact":"varicella","suffix":". On the contrary there are a few restraints for","offset":1864,"length":9}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/7a14d014-ecaf-3d0a-9997-c081493dff29":{"_typeGroup":"entities","_type":"MedicalCondition","forenduserdisplay":"false","name":"Tetanus","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/MedicalCondition","instances":[{"detection":"[and other infectious diseases like Rabies, ]Tetanus[, Hepatitis A&B and varicella. On the contrary]","prefix":"and other infectious diseases like Rabies, ","exact":"Tetanus","suffix":", Hepatitis A&B and varicella. On the contrary","offset":1837,"length":7}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/88e19fbc-3348-3843-b6c0-f8a6de4f82c6":{"_typeGroup":"entities","_type":"MedicalCondition","forenduserdisplay":"false","name":"Hemophilia","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/MedicalCondition","instances":[{"detection":"[of application the market is categorised as ]Hemophilia[, Primary Immunodeficiency Disorder, Idiopathic]","prefix":"of application the market is categorised as ","exact":"Hemophilia","suffix":", Primary Immunodeficiency Disorder, Idiopathic","offset":2422,"length":10}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/09bebb87-1ef5-373d-bd01-263e77470c65":{"_typeGroup":"entities","_type":"Continent","forenduserdisplay":"false","name":"Europe","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Continent","instances":[{"detection":"[is analysed in the regions of North America, ]Europe[, Asia-Pacific, Latin America and Middle-East &]","prefix":"is analysed in the regions of North America, ","exact":"Europe","suffix":", Asia-Pacific, Latin America and Middle-East &","offset":2631,"length":6}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/c22051cc-940f-3b60-9aad-fd141441c4b5":{"_typeGroup":"entities","_type":"Region","forenduserdisplay":"false","name":"Middle-East","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Region","instances":[{"detection":"[ America, Europe, Asia-Pacific, Latin America and ]Middle-East[ & Africa.\n\nThe major players in the plasma]","prefix":" America, Europe, Asia-Pacific, Latin America and ","exact":"Middle-East","suffix":" & Africa.\n\nThe major players in the plasma","offset":2671,"length":11}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/ad18b2f3-e9a0-32f3-8271-7e708b7f0182":{"_typeGroup":"entities","_type":"MedicalCondition","forenduserdisplay":"false","name":"neurological and bleeding disorders","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/MedicalCondition","instances":[{"detection":"[including autoimmune, immune deficiencies, ]neurological and bleeding disorders[. Plasma protein therapies are used to treat]","prefix":"including autoimmune, immune deficiencies, ","exact":"neurological and bleeding disorders","suffix":". Plasma protein therapies are used to treat","offset":1228,"length":35}],"relevance":0.2}}